ArticleAustralasian journal on ageing2026
Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single-Centre Tertiary Hospital.
Article in Australasian journal on ageing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveApixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes. This project aimed to review current prescribing practices of apixaban 2.5 mg against guidelines to identify potentially inappropriate prescribing.
methodA single-centre, retrospective review of all adult patients admitted to a large tertiary hospital in Perth, Australia, who were dispensed apixaban 2.5 mg between 1 January 2023 and 31 December 2024, was undertaken. Patients were identified via dispensing records. Demographics, indication, comorbidities, concurrent medications and laboratory data were collated. Each case was assessed against current guidelines to determine whether dosing was appropriate or potentially inappropriate. Data were analysed using quantitative statistics.
resultsA total of 303 patients were dispensed apixaban 2.5 mg in the audit period. Of these 178 (59%) were newly initiated. The mean age of the cohort was 79 years (standard deviation [SD] 12.6), with 49% female. Of the 128 patients (72%) newly initiated on apixaban 2.5 mg for non-valvular AF, 53 (41%) patients received a potentially inappropriate dose. A further 19 patients (11% of the entire cohort) received a potentially inappropriately low dose for acute VTE treatment.
conclusionsA significant proportion of patients initiated on apixaban 2.5 mg received potentially inappropriate doses. These findings highlight the need for targeted anticoagulation stewardship and clinician education to optimise patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.